Vaxart (VXRT) Stock Forecast, Price Target & Predictions
VXRT Stock Forecast
Vaxart stock forecast is as follows: an average price target of $2.00 (represents a 147.40% upside from VXRT’s last price of $0.81) and a rating consensus of 'Hold', based on 3 wall street analysts offering a 1-year stock forecast.
VXRT Price Target
The average price target for Vaxart (VXRT) is $2.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $2.00 to $2.00. This represents a potential 147.40% upside from VXRT's last price of $0.81.
VXRT Analyst Ratings
According to 3 Wall Street analysts, Vaxart's rating consensus is 'Hold'. The analyst rating breakdown for VXRT stock is 0 'Strong Buy' (0.00%), 1 'Buy' (33.33%), 2 'Hold' (66.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Vaxart Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jan 31, 2024 | Mayank Mamtani | B.Riley Financial | $2.00 | $1.18 | 69.49% | 147.40% |
The latest Vaxart stock forecast, released on Jan 31, 2024 by Mayank Mamtani from B.Riley Financial, set a price target of $2.00, which represents a 69.49% increase from the stock price at the time of the forecast ($1.18), and a 147.40% increase from VXRT last price ($0.81).
Vaxart Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $2.00 |
| Last Closing Price | $0.81 | $0.81 | $0.81 |
| Upside/Downside | -100.00% | -100.00% | 147.40% |
In the current month, the average price target of Vaxart stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Vaxart's last price of $0.81. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 15, 2024 | Oppenheimer | Outperform | Hold | Initialise |
| Aug 14, 2024 | Oppenheimer | - | Outperform | Initialise |
| Dec 19, 2022 | B. Riley Securities | Neutral | Neutral | Hold |
| Jun 12, 2021 | Piper Sandler | - | Overweight | Initialise |
Vaxart's last stock rating was published by Oppenheimer on Aug 15, 2024. The company Initialise its VXRT rating from "Outperform" to "Hold".
Vaxart Financial Forecast
Vaxart Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 17 | Mar 16 | Dec 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $446.00K | $1.36M | $675.00K | $22.00K | - | - | $85.00K | $74.00K | $200.00K | $112.00K | $506.00K | $356.00K | $265.00K | $523.00K | $2.90M | $3.92M | $454.00K | $85.00K | $4.90M | $5.30M | $1.70M |
| Avg Forecast | $400.00K | $200.00K | $200.00K | $200.00K | $20.83M | $1.93M | $100.00K | $800.00K | $833.33K | $100.00K | $83.33K | $800.00K | $675.00K | $50.00K | $96.75K | $125.00K | $182.75K | $118.40K | $549.25K | $617.00K | $4.35M | $1.07M | $1.27M | $2.80M | $600.00K | $443.00K | $1.10M | $9.55M | $6.81M | $1.10M |
| High Forecast | $400.00K | $200.00K | $200.00K | $200.00K | $20.83M | $2.73M | $100.00K | $800.00K | $1.48M | $100.00K | $83.33K | $800.00K | $675.00K | $50.00K | $96.75K | $125.00K | $182.75K | $118.40K | $549.25K | $617.00K | $4.35M | $1.07M | $1.27M | $2.80M | $600.00K | $443.00K | $1.10M | $11.45M | $8.18M | $1.32M |
| Low Forecast | $400.00K | $200.00K | $200.00K | $200.00K | $20.83M | $1.12M | $100.00K | $800.00K | $185.19K | $100.00K | $83.33K | $800.00K | $675.00K | $50.00K | $96.75K | $125.00K | $182.75K | $118.40K | $549.25K | $617.00K | $4.35M | $1.07M | $1.27M | $2.80M | $600.00K | $443.00K | $1.10M | $7.64M | $5.45M | $880.00K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | 9 | 8 | 6 | 10 | 14 | 8 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | 4.46% | 16.30% | 0.84% | 0.03% | - | - | 0.68% | 0.40% | 1.69% | 0.20% | 0.82% | 0.08% | 0.25% | 0.41% | 1.04% | 6.53% | 1.02% | 0.08% | 0.51% | 0.78% | 1.55% |
Vaxart's average Quarter revenue forecast for Dec 23 based on 2 analysts is $833.33K, with a low forecast of $185.19K, and a high forecast of $1.48M. VXRT's average Quarter revenue forecast represents a 86.85% increase compared to the company's last Quarter revenue of $446.00K (Sep 23).
Vaxart EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 17 | Mar 16 | Dec 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | 9 | 8 | 6 | 10 | 14 | 8 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-15.09M | $-22.53M | $-22.87M | $-17.44M | $-29.43M | $-27.87M | $-23.61M | $-19.20M | $-16.20M | $-14.76M | $-14.51M | $-12.49M | $-6.94M | $-7.89M | $-73.00K | $-4.93M | $-3.89M | $-4.01M | $-4.10M | $-5.20M | $-6.50M |
| Avg Forecast | $-377.76K | $-188.88K | $-188.88K | $-188.88K | $-19.68M | $-1.82M | $-94.44K | $-31.11M | $-786.99K | $-94.44K | $-78.70K | $-24.60M | $-637.47K | $-47.22K | $-91.37K | $-19.44M | $-172.59K | $-111.82K | $-518.71K | $-9.57M | $-4.11M | $-1.01M | $-1.20M | $-98.55K | $-566.63K | $-4.22M | $-1.04M | $-5.45M | $-6.36M | $-3.25M |
| High Forecast | $-377.76K | $-188.88K | $-188.88K | $-188.88K | $-19.68M | $-1.06M | $-94.44K | $-24.89M | $-174.89K | $-94.44K | $-78.70K | $-19.68M | $-637.47K | $-47.22K | $-91.37K | $-15.55M | $-172.59K | $-111.82K | $-518.71K | $-7.66M | $-4.11M | $-1.01M | $-1.20M | $-78.84K | $-566.63K | $-3.38M | $-1.04M | $-4.36M | $-5.08M | $-2.60M |
| Low Forecast | $-377.76K | $-188.88K | $-188.88K | $-188.88K | $-19.68M | $-2.58M | $-94.44K | $-37.34M | $-1.40M | $-94.44K | $-78.70K | $-29.52M | $-637.47K | $-47.22K | $-91.37K | $-23.33M | $-172.59K | $-111.82K | $-518.71K | $-11.49M | $-4.11M | $-1.01M | $-1.20M | $-118.26K | $-566.63K | $-5.07M | $-1.04M | $-6.54M | $-7.63M | $-3.90M |
| Surprise % | - | - | - | - | - | - | - | - | - | 159.78% | 286.29% | 0.93% | 27.35% | 623.18% | 305.02% | 1.21% | 111.28% | 144.92% | 28.45% | 1.52% | 3.04% | 6.89% | 6.60% | 0.74% | 8.70% | 0.92% | 3.86% | 0.75% | 0.82% | 2.00% |
undefined analysts predict VXRT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Vaxart's previous annual EBITDA (undefined) of $NaN.
Vaxart Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 17 | Mar 16 | Dec 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | 9 | 8 | 6 | 10 | 14 | 8 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | $-17.40M | $-22.55M | $-25.14M | $-23.92M | $-29.31M | $-29.43M | $-25.10M | $-20.76M | $-17.58M | $-16.12M | $-16.01M | $-13.86M | $-8.09M | $-8.98M | $-1.30M | $-6.41M | $-5.26M | $-5.64M | $-4.40M | $-5.20M | $-6.50M |
| Avg Forecast | $-20.32M | $-18.47M | $-18.47M | $-20.32M | $-1.82M | $-18.56M | $-27.71M | $-33.08M | $-24.63M | $-33.25M | $-33.25M | $-26.15M | $-42.02M | $-44.79M | $-38.79M | $-20.67M | $-30.48M | $-26.60M | $-26.32M | $-10.56M | $-10.16M | $-17.24M | $-11.70M | $-1.75M | $-24.01M | $-5.71M | $-92.35M | $-5.85M | $-6.36M | $-3.25M |
| High Forecast | $-20.32M | $-18.47M | $-18.47M | $-20.32M | $-1.82M | $-14.85M | $-27.71M | $-26.46M | $-21.34M | $-33.25M | $-33.25M | $-20.92M | $-42.02M | $-44.79M | $-38.79M | $-16.54M | $-30.48M | $-26.60M | $-26.32M | $-8.45M | $-10.16M | $-17.24M | $-11.70M | $-1.40M | $-24.01M | $-4.57M | $-92.35M | $-4.68M | $-5.08M | $-2.60M |
| Low Forecast | $-20.32M | $-18.47M | $-18.47M | $-20.32M | $-1.82M | $-24.13M | $-27.71M | $-39.69M | $-26.27M | $-33.25M | $-33.25M | $-31.38M | $-42.02M | $-44.79M | $-38.79M | $-24.81M | $-30.48M | $-26.60M | $-26.32M | $-12.68M | $-10.16M | $-17.24M | $-11.70M | $-2.10M | $-24.01M | $-6.85M | $-92.35M | $-7.01M | $-7.63M | $-3.90M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.52% | 0.68% | 0.96% | 0.57% | 0.65% | 0.76% | 1.21% | 0.68% | 0.66% | 0.61% | 1.52% | 1.36% | 0.47% | 0.77% | 0.74% | 0.27% | 0.92% | 0.06% | 0.75% | 0.82% | 2.00% |
Vaxart's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VXRT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Vaxart SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 17 | Mar 16 | Dec 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | 9 | 8 | 6 | 10 | 14 | 8 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | $4.92M | $5.60M | $6.63M | $6.45M | $6.96M | $9.32M | $6.66M | $5.75M | $5.04M | $5.15M | $5.94M | $5.13M | $4.19M | $3.90M | $1.99M | $1.33M | $1.46M | $1.38M | $1.30M | $1.50M | $1.50M |
| Avg Forecast | $24.48M | $12.24M | $12.24M | $12.24M | $1.28B | $117.81M | $6.12M | $48.96M | $51.00M | $6.12M | $5.10M | $48.96M | $41.31M | $3.06M | $5.92M | $7.65M | $11.18M | $7.25M | $33.62M | $37.76M | $266.23M | $65.28M | $77.52M | $2.69M | $36.72M | $27.11M | $67.32M | $1.73M | $1.83M | $750.00K |
| High Forecast | $24.48M | $12.24M | $12.24M | $12.24M | $1.28B | $167.14M | $6.12M | $48.96M | $90.67M | $6.12M | $5.10M | $48.96M | $41.31M | $3.06M | $5.92M | $7.65M | $11.18M | $7.25M | $33.62M | $37.76M | $266.23M | $65.28M | $77.52M | $3.22M | $36.72M | $27.11M | $67.32M | $2.07M | $2.20M | $900.00K |
| Low Forecast | $24.48M | $12.24M | $12.24M | $12.24M | $1.28B | $68.49M | $6.12M | $48.96M | $11.33M | $6.12M | $5.10M | $48.96M | $41.31M | $3.06M | $5.92M | $7.65M | $11.18M | $7.25M | $33.62M | $37.76M | $266.23M | $65.28M | $77.52M | $2.15M | $36.72M | $27.11M | $67.32M | $1.38M | $1.47M | $600.00K |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.80% | 1.10% | 0.14% | 0.16% | 2.27% | 1.57% | 0.87% | 0.51% | 0.70% | 0.15% | 0.16% | 0.02% | 0.06% | 0.05% | 0.74% | 0.04% | 0.05% | 0.02% | 0.75% | 0.82% | 2.00% |
Vaxart's average Quarter SG&A projection for Dec 23 is $51.00M, based on 2 Wall Street analysts, with a range of $11.33M to $90.67M. The forecast indicates a 936.41% rise compared to VXRT last annual SG&A of $4.92M (Sep 23).
Vaxart EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 17 | Mar 16 | Dec 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | 9 | 8 | 6 | 10 | 14 | 8 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.11 | $-0.00 | $-0.19 | $-0.19 | $-0.23 | $-0.23 | $-0.20 | $-0.17 | $-0.14 | $-0.13 | $-0.14 | $-0.13 | $-0.08 | $-0.12 | $-0.02 | $-0.13 | $-0.32 | $-0.39 | $-1.25 | $-1.48 | $-1.85 |
| Avg Forecast | $-0.11 | $-0.10 | $-0.10 | $-0.11 | $-0.01 | $-0.10 | $-0.15 | $-0.14 | $-0.13 | $-0.18 | $-0.18 | $-0.19 | $-0.23 | $-0.24 | $-0.21 | $-0.16 | $-0.17 | $-0.14 | $-0.14 | $-0.10 | $-0.06 | $-0.09 | $-0.06 | $-0.04 | $-0.13 | $-0.35 | $-0.50 | $-3.07 | $-2.42 | $-0.05 |
| High Forecast | $-0.11 | $-0.10 | $-0.10 | $-0.11 | $-0.01 | $-0.08 | $-0.15 | $-0.14 | $-0.12 | $-0.18 | $-0.18 | $-0.19 | $-0.23 | $-0.24 | $-0.21 | $-0.16 | $-0.17 | $-0.14 | $-0.14 | $-0.10 | $-0.06 | $-0.09 | $-0.06 | $-0.04 | $-0.13 | $-0.35 | $-0.50 | $-2.46 | $-1.94 | $-0.04 |
| Low Forecast | $-0.11 | $-0.10 | $-0.10 | $-0.11 | $-0.01 | $-0.13 | $-0.15 | $-0.14 | $-0.14 | $-0.18 | $-0.18 | $-0.19 | $-0.23 | $-0.24 | $-0.21 | $-0.16 | $-0.17 | $-0.14 | $-0.14 | $-0.10 | $-0.06 | $-0.09 | $-0.06 | $-0.04 | $-0.13 | $-0.35 | $-0.50 | $-3.68 | $-2.90 | $-0.07 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.61% | 0.00% | 1.02% | 0.84% | 0.95% | 1.10% | 1.23% | 1.03% | 0.97% | 0.91% | 1.40% | 2.36% | 0.86% | 1.89% | 0.50% | 1.00% | 0.90% | 0.78% | 0.41% | 0.61% | 37.00% |
According to undefined Wall Street analysts, Vaxart's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VXRT previous annual EPS of $NaN (undefined).
VXRT Forecast FAQ
Is Vaxart a good buy?
No, according to 3 Wall Street analysts, Vaxart (VXRT) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 33.33% of VXRT's total ratings.
What is VXRT's price target?
Vaxart (VXRT) average price target is $2 with a range of $2 to $2, implying a 147.40% from its last price of $0.808. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Vaxart stock go up soon?
According to Wall Street analysts' prediction for VXRT stock, the company can go up by 147.40% (from the last price of $0.808 to the average price target of $2), up by 147.40% based on the highest stock price target, and up by 147.40% based on the lowest stock price target.
Can Vaxart stock reach $1?
VXRT's average twelve months analyst stock price target of $2 supports the claim that Vaxart can reach $1 in the near future.
What are Vaxart's analysts' financial forecasts?
Vaxart's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $23.66M (high $24.47M, low $22.85M), average EBITDA is $-52.702M (high $-45.718M, low $-59.686M), average net income is $-81.169M (high $-70.841M, low $-93.354M), average SG&A $1.45B (high $1.5B, low $1.4B), and average EPS is $-0.4 (high $-0.38, low $-0.431). VXRT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1M (high $1M, low $1M), average EBITDA is $-944K (high $-944K, low $-944K), average net income is $-77.575M (high $-77.575M, low $-77.575M), average SG&A $61.2M (high $61.2M, low $61.2M), and average EPS is $-0.42 (high $-0.42, low $-0.42).
Did the VXRT's actual financial results beat the analysts' financial forecasts?
Based on Vaxart's last annual report (Dec 2022), the company's revenue was $107K, which missed the average analysts forecast of $946.75K by -88.70%. Apple's EBITDA was $-106M, beating the average prediction of $-20.22M by 424.63%. The company's net income was $-108M, missing the average estimation of $-146M by -26.33%. Apple's SG&A was $29.39M, missing the average forecast of $57.94M by -49.28%. Lastly, the company's EPS was $-0.84, missing the average prediction of $-0.842 by -0.30%. In terms of the last quarterly report (Sep 2023), Vaxart's revenue was $446K, beating the average analysts' forecast of $100K by 346.00%. The company's EBITDA was $-15.089M, beating the average prediction of $-94.439K by 15877.51%. Vaxart's net income was $-17.4M, missing the average estimation of $-33.247M by -47.66%. The company's SG&A was $4.92M, missing the average forecast of $6.12M by -19.59%. Lastly, the company's EPS was $-0.11, missing the average prediction of $-0.18 by -38.89%